Generate Biomedicines Inc. (GENB) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 41% of 52W Range • RSI-14 at 52.8 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 61/100 (C-) score, GENB faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.00) or 200D SMA ($14.07) invalidates the momentum regime and cuts Target Base ($15.98) toward Bear Floor ($12.46).
Generate Biomedicines Inc. (GENB) surged +2.54% to $15.77, trading at 41% of its 52-week range ($11 – $22.67). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
Generate Biomedicines has moved back into focus after a sharp weekly gain, which puts fresh attention on whether the current share price lines up with the value carried on its balance sheet. With book value now in the sp
Anthropic outlined collaborations with six organizations, including Bristol Myers Squibb, Generate Biomedicines and BigHat Biosciences.
SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at the following investor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GENB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GENB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Generate Biomedicines Inc. (GENB) ranks #184 by composite RQD confidence (61/100, grade C-) and #262 by equity capitalization ($2.02B). Within this direct 5-issuer industry benchmark cohort, GENB leads on earnings valuation at N/A trailing P/E, while SLS leads on capital efficiency and profitability with -21.8% ROIC and — gross margin. GENB currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GENB
ACTIVE
Generate Biomedicines Inc. | C- | 61/100 | — | — | — | +2.54% | $2.02B | Benchmark Subject |
| ZYME Zymeworks Inc. | D | 47/100 | — | — | -32.2% | -0.66% | $2.02B | /zyme-vs-genb → |
| SRPT Sarepta Therapeutics Inc. | D- | 35/100 | — | 96.0% | -35.0% | -0.47% | $2.03B | /srpt-vs-genb → |
| SLS SELLAS Life Sciences Group Inc. | D- | 35/100 | — | — | -21.8% | -2.17% | $2.05B | /sls-vs-genb → |
| TRVI Trevi Therapeutics Inc. | D- | 39/100 | — | — | -23.7% | +2.15% | $1.97B | /trvi-vs-genb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Generate Biomedicines Inc. (GENB) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, GENB closed FY2025 with $330.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $330.2M | — |
As of 2026-11-01, Generate Biomedicines Inc. (NASDAQ: GENB) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $15.77 (+2.54% 1D, market cap $2.02B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GENB ranks #184 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GENB carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ZYME (Zymeworks Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B) and SRPT (Sarepta Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B). Among the 5-stock peer group, GENB leads on earnings multiple (N/A) while SLS leads on capital efficiency (-21.8% ROIC).
Per GENB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002100782), Generate Biomedicines Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $330.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
GENB last traded at $15.77 (+2.54% on volume of 1,762,250 shares), positioning the stock +5.13% above its 50-day simple moving average ($15.00) and +12.08% above its 200-day simple moving average ($14.07). Across its 52-week range of $11.00 to $22.67, GENB sits at the 40.9% percentile with a 14-day RSI of 52.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.80 to $17.74).
Why GENB Stock surged +2.54% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.